Want to see CVSI full AI Analyst Report?
CVSI Stock Chart & Stats
$0.02
>-$0.01(-5.72%)
At close: 4:00 PM EDT
$0.02
>-$0.01(-5.72%)
Day’s Range― - ―
52-Week Range$0.01 - $0.10
Previous CloseN/A
Volume53.78K
Average Volume (3M)454.79K
Market Cap
$4.22M
Enterprise Value$5.97
Total Cash (Recent Filing)$266.00K
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta0.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding225,829,130
10 Day Avg. Volume375,728
30 Day Avg. Volume454,791
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Retail Brand PositionMaintaining the #1 hemp extract brand position in natural product retail gives CV Sciences a recognized platform for distribution and repeat demand. That standing can support retailer access and provide leverage as the company adds products and expands into adjacent wellness categories.
Cost And Cash-Flow ImprovementLower operating expenses, improved adjusted EBITDA, and a shift to positive quarterly operating cash flow indicate meaningful operating discipline. If sustained, these gains can reduce cash burn, improve resilience, and move the company closer to self-funding its operations.
Product Diversification And InsourcingExpansion into non-cannabinoid products, acquisitions, and internal manufacturing broadens CV Sciences’ addressable wellness market and reduces reliance on one product category. Expected cost and speed benefits could strengthen margins and support more consistent innovation over time.
Bears Say
Declining Revenue And UnitsPersistent declines in revenue and unit volume indicate that CV Sciences is still facing weak demand and regulatory pressure in its core category. Continued top-line contraction can reduce operating leverage, limit investment capacity, and make the path to sustained profitability more difficult.
Ongoing Losses And Negative TTM Cash FlowThe company remains structurally unprofitable on a trailing basis despite relatively stable gross margin. Negative operating and free cash flow show that the business is not consistently self-funding, increasing dependence on operational recovery or external capital to support ongoing activities.
Low LiquidityA cash balance of roughly $0.3 million provides limited liquidity relative to the company’s continuing losses and operating needs. This reduces flexibility to absorb further sales weakness, fund product initiatives, or manage regulatory changes without relying on additional financing.
CV Sciences News
CVSI FAQ
What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
What is CV Sciences Inc’s market cap?
CV Sciences Inc’s market cap is $4.22M.
When is CV Sciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CV Sciences Inc’s earnings last quarter?
Currently, no data Available
Is CV Sciences Inc overvalued?
According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued.
Does CV Sciences Inc pay dividends?
CV Sciences Inc does not currently pay dividends.
What is CV Sciences Inc’s EPS estimate?
CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CV Sciences Inc have?
CV Sciences Inc has 225,829,130 shares outstanding.
What happened to CV Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CV Sciences Inc?
Currently, no hedge funds are holding shares in CVSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CV Sciences Inc
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
CVSI Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
cbdMD
―
Cosmos Holdings
―
IM Cannabis Corp
―
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
11.80% Insiders
<0.01% Other Institutional Investors
88.20% Public Companies and
Individual Investors










